In a stunning setback, Amarin loses big patent fight over Vascepa IP. And its high-flying stock crashes to earth
Amarin’s shares $AMRN were blitzed Monday evening, losing billions in value as reports spread that the company had lost its high-profile effort to keep its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
